Cargando…

The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients

IMPORTANCE: Sinonasal symptoms in patients suffering from cystic fibrosis can negatively influence the quality of life and sinuses can be a niche for pathogens causing infection and inflammation leading to a decrease of lung function. Ivacaftor, a potentiator of the Cystic Fibrosis Transmembrane Con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gostelie, Romee, Stegeman, Inge, Berkers, Gitte, Bittermann, Joost, Ligtenberg-van der Drift, Ivonne, van Kipshagen, Peter-Jan, de Winter - de Groot, Karin, Speleman, Lucienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371187/ https://www.ncbi.nlm.nih.gov/pubmed/32687499 http://dx.doi.org/10.1371/journal.pone.0235638

Ejemplares similares

Long‐term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation
por: Burghard, M (Marcella), et al.
Publicado: (2020)

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation
por: Kristensen, Maartje I., et al.
Publicado: (2021)

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype delta F508/S1215N
por: Berkhout, Maaike, et al.
Publicado: (2015)

1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
por: Milgrom, Alexander, et al.
Publicado: (2019)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

1251. Strengthening Antimicrobial Stewardship Programs through Public Health Support
por: Kriengkauykiat, Jane, et al.
Publicado: (2023)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

A Descriptive Analysis of 1251 Solid Organ Transplant Visits to the Emergency Department
por: Unterman, Sarah, et al.
Publicado: (2009)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability
por: Vonk, Steffie E. M., et al.
Publicado: (2021)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

P1251: BONE-BASED 3D SCAFFOLD AS AN IN-VITRO MODEL OF MICROENVIRONMENT-LYMPHOMA INTERACTION
por: Ceccato, J., et al.
Publicado: (2022)

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
por: Neerincx, Anne H., et al.
Publicado: (2021)

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome
por: Marsh, Ryan, et al.
Publicado: (2023)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
por: O’Reilly, Ruth, et al.
Publicado: (2013)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis–Related Diabetes
por: Christian, Francis, et al.
Publicado: (2019)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
por: Mésinèle, Julie, et al.
Publicado: (2022)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Measured transverse‐axis dosimetric parameters of the model STM1251 [Formula: see text] interstitial source
por: Li, Z., et al.
Publicado: (2002)

Sinonasal Manifestations in Cystic Fibrosis
por: Oomen, Karin P. Q., et al.
Publicado: (2012)

Effect of Gonadotropin Types and Indications on Homologous Intrauterine Insemination Success: A Study from 1251 Cycles and a Review of the Literature
por: Cabry-Goubet, Rosalie, et al.
Publicado: (2017)

1251. Contaminated Sinks May be an Environmental Source for Serial Transmission of Carbapenem-Resistant Enterobacteriaceae (CRE) to ICU Patients
por: Lewis, Sarah S, et al.
Publicado: (2018)

Bridging for lung transplantation with lumacaftor/ivacaftor
por: Pedersen, Søren Sperling, et al.
Publicado: (2018)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
por: Connett, GJ
Publicado: (2019)

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
por: Shiferaw, Dejene, et al.
Publicado: (2019)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
por: Csanády, László, et al.
Publicado: (2019)

Effect of Ivacaftor on Objective and Subjective Measures of Cough in Patients with Cystic Fibrosis
por: Faruqi, Shoaib, et al.
Publicado: (2016)

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
por: Hisert, Katherine B., et al.
Publicado: (2020)

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
por: Colombo, C., et al.
Publicado: (2021)

Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator
por: Laselva, Onofrio, et al.
Publicado: (2021)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis
por: King, Susannah J., et al.
Publicado: (2021)

Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
por: Causer, Adam J., et al.
Publicado: (2022)

Ivacaftor: Five‐year outcomes in the West of Scotland cystic fibrosis population
por: Al‐Din, Yasmin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6hrc0dbivpruefoghs45vbs9vp